The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement
Oslo, June 27[th], 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic Lateral Sclerosis – ALS.TikoMed has previously completed and reported on two successful phase 2a clinical studies in ALS, one at the Sahlgrenska University Hospital in Sweden and one at the University of Birmingham in the UK, both with promising